Preclinical models serve as indispensable tools in translational medicine. Specifically,
patient-derived models such as patient-derived xenografts (PDX), induced pluripotent stem …

Functional precision medicine (fPM) offers an exciting, simplified approach to finding the
right applications for existing molecules and enhancing therapeutic potential. Integrative and …

Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases which accounts
for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset …

Background Brain tumors are the deadliest solid tumors in children and adolescents. Most of
these tumors are glial in origin and exhibit strong heterogeneity, hampering the …

Treatment with anaplastic lymphoma kinase (ALK) inhibitors significantly improves outcome
for non‐small‐cell lung cancer (NSCLC) patients with ALK‐rearranged tumors. However …

Preclinical tumor models with native tissue microenvironments provide essential tools to
understand how heterogeneous tumor phenotypes relate to drug response. Here we present …

Preclinical tumor models with native tissue microenvironments provide essential tools to
understand how heterogeneous tumor phenotypes relate to drug response. Here we present …

Non-small cell lung cancer (NSCLC) constitutes over 85% of lung cancer. Histologically,
NSCLC can be broadly classified into adenocarcinoma (AC), squamous cell carcinoma …

Drug sensitivity data acquired from solid tumor-derived cultures are often unsuitable for
personalized treatment guidance due to the lengthy turnaround time. Here, we present a …

For non-small cell lung cancer (NSCLC) patients with ALK-rearranged tumors, treatment
with ALK inhibitors can improve outcomes. However, clinical resistance typically develops …